Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (277)
- COVID-19 (163)
- Safety monitoring and information (100)
- Legislation (95)
- Compliance and enforcement (70)
- Manufacturing (55)
- Vaping hub (54)
- Labelling and packaging (37)
- Import and export (28)
- Scheduling (national classification system) (27)
- Medicinal cannabis hub (25)
- Sunscreens (16)
- Shortages and supply disruptions (14)
- Weight loss products (14)
- Committees and advisory bodies (9)
- Cosmetics (5)
- Unique Device Identification (UDI) hub (4)
- Clinical trials (3)
- Fees and payments (2)
- Prescription opioids hub (2)
- Urogynaecological (transvaginal) surgical mesh hub (2)
- Breast implant hub (1)
Search
1262 result(s) found, displaying 1126 to 1150
-
Safety updatesThe TGA completed a desktop review of selected listed sunscreen products.
-
Safety updatesBe aware of cross-reactivity with home-use self-test ovulation kits, TGA undertakes product safety review into intragastric balloon systems
-
Media releasesOur annual survey measures satisfaction with a range of services and activities including our role and performance
-
Media releasesApalutamide (Erlyand) is the first medicine approved via ACSS Consortium’s NCE working group
-
Media releasesConsumers can now report dodgy ads for medicines and medical devices through a single online form
-
Safety updatesOral methotrexate dosing, medicines associated with a risk of neuropsychiatric adverse events, and clozapine and gastrointestinal effects
-
BlogCaitlin's story explains how a patient in Australia can legally access medicinal cannabis.
-
News articlesList of OTC codeine-containing products moving to prescription only
-
Regulatory decision noticesThis instrument applies to an application to list a complementary medicine under section 26AE of the Act.
-
Regulatory decision noticesThis instrument applies to an application to list a medicine under section 26 or 26A of the Act.
-
Regulatory decision noticesThis instrument applies to an application to register a complementary medicine
-
Safety updatesHow TGA uses joint replacement registry data; Focus on skills for vacuum-assisted births; TGA reviews product safety of ventilators
-
Regulatory decision noticesTherapeutic Goods (Provisional Determinations and Orphan Drug Designations-Extension) Approval of Application Form.
-
Regulatory decision noticesThis instrument applies to the online form titled Prescription Medicines Designation/Determination Application in the TGA's electronic lodgement facility, completed in accordance with the relevant instructions in that form.
-
Media releasesInformation about influenza vaccines for use in 2018
-
Media releasesIn reference to the ABC’s Fact Check article “Will the move to make codeine prescription-only save a100 lives a year” the Therapeutic Goods Administration (TGA) would like to clarify:
-
News articlesInformation to help sponsors understand the provisional approval pathway for prescription medicines.
-
Safety updatesFirst-generation oral sedating antihistamines – use in children, Suvorexant (Belsomra) – next day effects, Desvenlafaxine (Pristiq) recommended dose, Miconazole and potential interaction with warfarin
-
Safety updatesPreventable alarm issues; Review into cochlear implants; NHS cylinder alert; recent safety alerts
-
Regulatory decision noticess23 instruments supporting the new COR process have been updated.
-
Regulatory decision noticess23 instruments supporting the new COR process have been updated.
-
Media releasesThe medicines’ regulator is not proposing and will not be stopping GPs from prescribing high dose opioids
-
Media releasesThe TGA has issued a discussion paper on the use and misuse of prescription strong opioids, such as oxycodone, and whether there is a need for specific regulatory responses
-
Safety updatesInappropriate use of scalpel removers; ransomware named as 2018's 'top hazard'; joint registry data; recent safety alerts
-
Regulatory decision noticesArrangement under subsection 7C(1) of the Therapeutic Goods Act 1989 for use of computer programs to make decisions under paragraph 61(2)(a)(iii) of the Act to release information from the Adverse Event Management System to the World Health Organization.